On 6/mar/2024, fresenius became aware this patient with end stage renal disease (esrd) on continuous cyclic peritoneal dialysis [cc(pd)] utilizing a liberty select cycler and liberty cycler set for renal replacement therapy (rrt) was hospitalized on (b)(6) 2024 due to suspected peritonitis.No additional information was provided during intake.Follow-up with the patient¿s pd registered nurse (pdrn) confirmed the patient was admitted on
(b)(6) 2024 with complaints of leg pain and weakness.Further testing revealed the patient was experiencing ¿significant¿ hyperkalemia (value not provided), however it is unclear what, if any, medical intervention was provided.Per the patient¿s nephrologist, causality was attributed to peritoneal membrane failure.A peritoneal effluent fluid culture and cell count were collected on admission and despite the results being negative, the patient¿s peritoneal effluent fluid was cloudy.Therefore, the patient was initially treated with vancomycin and ceftazidime, however due to persistently cloudy peritoneal effluent fluid the patient¿s ceftazidime was discontinued and replaced with meropenem (route, frequency, dose not provided).The patient was diagnosed with suspected peritonitis and the antibiotic course will continue through (b)(6) 2024.As of
(b)(6) 2024, the patient remained hospitalized and was scheduled to be discharged in the next few days.The patient has recovered from the serious adverse events and will resume utilizing the same liberty select cycler following discharge.Per the pdrn, the serious adverse events were not caused by a fresenius device(s) and/or product(s) malfunction or deficiency.
|